Which drug works better after infant valve surgery? new study compares mirabegron and oxybutynin
NCT ID NCT07668232
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study looked at two drugs, mirabegron and oxybutynin, in 52 children over age 3 who had surgery for posterior urethral valves. The goal was to see which drug better improves bladder and kidney function and reduces urinary tract infections. Researchers also checked safety by monitoring blood pressure and heart rate.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Mirabegron and oxybutynin
- What this could lead to
- If successful, this could show that mirabegron is a safer or more effective option than oxybutynin for managing bladder function after valve surgery in children.
- What could go wrong
- This is a small, completed trial with only 52 participants, so results may not apply to all children. The study compares two existing drugs, so no major breakthrough is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
52 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
3 to 12 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- All children older than 3 years old who have undergone posterior urethral valve ablation Exclusion Criteria: * Children younger than 3 years old. * Children with residual valve. * Children who had undergone urinary diversion (vesicostomy or ureterostomy). * Children with other conditions that can potentially affect upper or lower urinary tract function (spina bifida, anorectal malformation,prune belly syndrome).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Posterior urethral valve are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Qina University hospital, South Valley University Hospital
Qina, South Valley, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.